Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 2
2011 4
2013 1
2014 1
2015 2
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Biologics-induced autoimmune diseases.
Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Perez-Alvarez R, et al. Curr Opin Rheumatol. 2013 Jan;25(1):56-64. doi: 10.1097/BOR.0b013e32835b1366. Curr Opin Rheumatol. 2013. PMID: 23114587 Review.
Autoimmune diseases induced by biological agents: a double-edged sword?
Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Ramos-Casals M, et al. Autoimmun Rev. 2010 Jan;9(3):188-93. doi: 10.1016/j.autrev.2009.10.003. Epub 2009 Oct 23. Autoimmun Rev. 2010. PMID: 19854301 Review.
Etanercept and uveitis: friends or foes?
Brito-Zerón P, Perez-Alvarez R, Ramos-Casals M; BIOGEAS Study Group. Brito-Zerón P, et al. Curr Med Res Opin. 2015 Feb;31(2):251-2. doi: 10.1185/03007995.2014.993024. Epub 2014 Dec 5. Curr Med Res Opin. 2015. PMID: 25438042 No abstract available.
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J; BIOGEAS Study Group. Ramos-Casals M, et al. Clin Exp Rheumatol. 2010 Jul-Aug;28(4):468-76. Epub 2010 Aug 30. Clin Exp Rheumatol. 2010. PMID: 20525449
Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ, Ayala-Gutiérrez MM, Callejas JL, Martínez-Berriotxoa A, Rascón J, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Gómez-de-la-Torre R, Sáez L, Canora-Lebrato J, Camps MT, Ortego-Centeno N, Castillo-Palma MJ, Ramos-Casals M; BIOGEAS Study Group. Díaz-Lagares C, et al. Arthritis Res Ther. 2011 Jul 11;13(4):R112. doi: 10.1186/ar3397. Arthritis Res Ther. 2011. PMID: 21745378 Free PMC article.
Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
Brito-Zerón P, Bosch X, Pérez-de-Lis M, Pérez-Álvarez R, Fraile G, Gheitasi H, Retamozo S, Bové A, Monclús E, Escoda O, Moreno A, López-Guillermo A, Khamashta MA, Ramos-Casals M; BIOGEAS Study Group. Brito-Zerón P, et al. Semin Arthritis Rheum. 2016 Feb;45(4):391-9. doi: 10.1016/j.semarthrit.2015.07.004. Epub 2015 Jul 14. Semin Arthritis Rheum. 2016. PMID: 26277577
Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.
Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, Retamozo S, Bové A, Bosch X, Sanchez-Tapias JM, Forns X, Ramos-Casals M; BIOGEAS Study Group. Pérez-Alvarez R, et al. Medicine (Baltimore). 2011 Nov;90(6):359-371. doi: 10.1097/MD.0b013e3182380a76. Medicine (Baltimore). 2011. PMID: 22033451 Free article.